Hypersensitivity Pneumonitis clinical trials at University of California Health
2 research studies open to eligible people
open to eligible people ages 18-85
Up to 135 patients with hypersensitivity pneumonitis will be enrolled at 5 clinical centers across the United States. Patients will be followed for 24 months to determine if biomarkers in the blood can predict disease progression.
at UC Davis
open to eligible people ages 18 years and up
This is a prospective exploratory biodistribution study in patients with interstitial lung disease (ILD). The purpose of this research study is to determine where and to which degree the FAPI tracer (68Ga-FAPI-46) accumulates in normal and fibrotic lung tissues of patients with interstitial lung disease. The study will include patients with interstitial lung disease with fibrotic lesions who are scheduled to undergo lung biopsy or transplantation. The study will include 30 patients, the upper limit for PET imaging studies conducted under the Radioactive Drug Research Committee (RDRC) purview. Participants will be injected with up to 7 mCi of 68-GaFAPi and will undergo one PET/CT scan. The study is sponsored by Ahmanson Translational Theranostic Division at UCLA.
Our lead scientists for Hypersensitivity Pneumonitis research studies include Jeremie Calais.